Enesi Pharma appoints Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations

Experienced leader in clinical operations joins Enesi to drive the development of vaccine programmes enabled using its innovative ImplaVax® solid dose, needle-free technology

Oxford, UK, 7 September 2021 – Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations.

Ms. Eagling-Vose brings over 20 years’ experience in the pharmaceutical industry, with a strong background in clinical development and a proven track record of driving results-focused operational excellence.

Prior to joining Enesi, she was Senior Director and Head of Clinical Operations at Vaccitech (UK), a vaccine company spun out from Oxford University. She worked alongside the senior leadership to set strategy while building high functioning teams and successfully leading all programmes into early-stage clinical studies.

Prior to Vaccitech, Ms. Eagling-Vose was Project Director and Director of Patient Engagement at Covance, an international contract research organisation, building collaborative networks of patient advocates and managing clinical programmes with large pharmaceutical clients.

She also led a number of clinical programmes at Vectura (UK), a leading inhaled product development company leveraging proprietary device and formulation technologies, during a period of acquisition and growth, creating and implementing vendor procurement and management processes, and successfully completing first in human clinical studies.

Ms. Eagling-Vose gained an MBA and a BSc (Hons) in biology with analytical science from the University of Liverpool (UK).

“We are excited to welcome Liz to Enesi. She brings impressive clinical development and operational experience, especially in the areas of vaccines and novel drug-delivery technologies,” said David Hipkiss, Chief Executive Officer of Enesi Pharma. “This expertise will be crucial to the team as we build out our internal capabilities both to support our multiple collaborations and to advance inhouse ImplaVax®-enabled programmes towards clinical development in multiple disease areas.”

“I am excited to join Enesi, whose innovative ImplaVax® technology is showing great potential across a broad range of disease areas,” added Ms. Eagling-Vose. “Enesi is clearly committed to improving access to and uptake of life-saving vaccines around the world, and ImplaVax® has the potential to overcome many of the challenges with traditional vaccination approaches. I look forward to being part of this highly motivated team and to help realise the potential of ImplaVax® to improve human health globally.”